By Stephen Nakrosis
The Food and Drug Administration approved Mirum Pharmaceuticals' Ctexli to treat Cerebrotendinous Xanthoma, a very rare lipid-storage disease.
The approval makes Ctexli, or chenopod, the first FDA-approved drug to treat CTX, the agency said Friday.
Patients with CTX are unable to break down cholesterol in a normal way, which can result in damage to the brain, liver, and skin and tendons, the FDA said.
The FDA also said the recommended dosage is 250 milligrams, taken orally three times a day.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
The Food and Drug Administration approved Mirum Pharmaceuticals' Ctexli, or chenodiol, to treat Cerebrotendinous Xanthoma, the agency said Friday. "FDA Approves Mirum Pharmaceuticals Treatment for Lipid-Storage Disease," at 1:04 p.m. ET, incorrectly said the treatment was chenopod.
(END) Dow Jones Newswires
February 21, 2025 17:49 ET (22:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.